Search results for "PPAR"

showing 10 items of 1686 documents

Vasospastic angina and scombroid syndrome: a case report

2012

Scombroid syndrome is a fish poisoning characterised by the onset of symptoms compatible with a pseudoallergic reaction; it is rarely also responsible of signs and symptoms of acute coronary syndromes, as demonstrated in this case report.

MaleTunaCoronary StenosisCoronary VasospasmAngina scombroid syndromeMiddle AgedCoronary AngiographySettore MED/11 - Malattie Dell'Apparato CardiovascolareAngina PectorisFoodborne DiseasesElectrocardiographyTachycardia SinusAnimalsHumansAngioplasty Balloon CoronaryHistamine
researchProduct

How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016

2020

Purpose. To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions. Methods. Four regional claims databases were used to measure drug prevalence, compare dosing intervals to those recommended in the summary of product characteristics (SPC), and identify switchers. Bilateral treatment and diabetic macular edema (DME) coding algorithms were validated, linking claims with a sample of prospectively collected ophthalmological data. Results. Overall, 41,836 patients received ≥1 study drug in 2010–2016 (4.8 per 10,000 persons). In 2016, anti-VEGF drug use ranged from 0.8 (Basilicata) to 5.7 (Lombardy) per 10,000 persons while intravitreal dexamethasone use ranged from 0…

MaleVascular Endothelial Growth Factor A0301 basic medicineintravitrealAngiogenesis Inhibitorsalgorithm.0302 clinical medicineMedicineSummary of Product Characteristicsmedia_commonAged 80 and overDrug ImplantsvalidationLaser CoagulationRGeneral MedicineMiddle AgedItalyanti-VEGF030220 oncology & carcinogenesisMedicineFemaleclinical dataoriginal articleResearch Articlemedicine.drugDrugmedicine.medical_specialtyArticle Subjectmedia_common.quotation_subjectMEDLINEdexamethasonePharmacyMacular EdemaGeneral Biochemistry Genetics and Molecular BiologyInsurance Claim Review03 medical and health sciencesRanibizumabInternal medicineHumansDosingDexamethasoneAgedDiabetic RetinopathyGeneral Immunology and MicrobiologySettore MED/30 - Malattie Apparato Visivobusiness.industryclaims database030104 developmental biologydrug utilisationMacular Edema; Ranibizumab; Laser CoagulationImplantRanibizumabbusinessBioMed Research International
researchProduct

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

2014

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). METHODS: This was a prospective multicenter randomized nonblinded trial. RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was…

MaleVascular Endothelial Growth Factor AVisual Acuity/drug effectsVisual acuitygenetic structuresVisual AcuityAngiogenesis Inhibitorslaw.inventionBevacizumab/therapeutic use0302 clinical medicineRandomized controlled triallawMyopiaMedicineProspective StudiesProspective cohort studyPathological myopiaAged 80 and overMiddle AgedSensory SystemsBevacizumabVascular endothelial growth factor AChoroidal neovascularizationIntravitreal InjectionsMyopia DegenerativeFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabNeuroscience(all)CNVBevacizumab; CNV; Pathological myopia; Ranibizumab.Antibodies Monoclonal HumanizedRanibizumab/therapeutic use03 medical and health sciencesCellular and Molecular NeuroscienceOphthalmologyRanibizumabVascular Endothelial Growth Factor A/antagonists & inhibitorsHumansAngiogenesis Inhibitors/therapeutic useIntravitreal bevacizumabAgedpathological myopia CNV bevacizumab ranibizumabSettore MED/30 - Malattie Apparato Visivobusiness.industryTherapeutic effectChoroidal Neovascularization/drug therapyeye diseasesChoroidal NeovascularizationOphthalmologyRegimen030221 ophthalmology & optometryMyopia Degenerative/drug therapysense organsRanibizumabbusiness030217 neurology & neurosurgeryFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southe…

2022

Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on vi…

MaleVascular Endothelial Growth Factor Agenetic structuresPharmacology &ltPHARMACOLOGY diabetic macular edema &ltbiostatisticsAngiogenesis InhibitorsDexamethasoneMacular DegenerationCATARACTRetinal DiseasesRanibizumabRetinal Vein OcclusionHumansProspective StudiesRETINAAgedAged 80 and overPharmacologySettore MED/30 - Malattie Apparato Visivopathologic myopiaGeneral MedicineMiddle AgedBevacizumabOphthalmologyLENSRETINA epidemiology / biostatistics pathologic myopia retina - medical therapies &ltIntravitreal InjectionsPharmacology diabetic macular edema RETINA epidemiology biostatisticsLENSCATARACTpathologic myopiaFemaleepidemiologydiabetic macular edemaEuropean Journal of Ophthalmology
researchProduct

Postoperative endophthalmitis incidence after intravitreal therapy: a comparison of two different preoperative antibiotic prophylaxis.

2016

Prevention of postoperative endophthalmitis (POE) is a goal of every ophthalmic procedure and also in intravitreal therapy (IVT). This comparative retrospective study targets whether systemic and topical preoperative antibiotic prophylaxis (PAP) regimen does prevent POE after IVT in a higher rate compared with topical PAP alone. Out of 6111 IVT performed over a period of 103.5 months, in the study group A patients were treated with systemic and topical PAP (2881 IVT), and in the study group B patients were treated only with topical PAP (3230 IVT). Intravitreal drugs were anti-VEGF, triamcinolone and dexamethasone implants. The incidence of POE in group A (1/2881 or 0.035 % per injection) wa…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyTriamcinolone acetonideAngiogenesis InhibitorsTriamcinolone AcetonideGroup BDexamethasone03 medical and health sciences0302 clinical medicineEndophthalmitisPostoperative ComplicationsAntibiotic prophylaxiPreoperative CaremedicineHumansEndophthalmitiAntibiotic prophylaxisGlucocorticoidsDexamethasoneAgedRetrospective StudiesAged 80 and overDrug ImplantsEndophthalmitisDose-Response Relationship DrugSettore MED/30 - Malattie Apparato Visivobusiness.industryIncidence (epidemiology)IncidenceIntravitreal therapyRetrospective cohort studyAntibiotic ProphylaxisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsOphthalmologyRegimenAnesthesiaIntravitreal Injections030221 ophthalmology & optometryFemalebusiness030217 neurology & neurosurgerymedicine.drugInternational ophthalmology
researchProduct

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

2010

PURPOSE The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuitymonoclonalAngiogenesis InhibitorsAntibodies Monoclonal HumanizedLoading doseChoroidal neovascularization; male; treatment outcome; injections; middle aged; vascular endothelial growth factor a; female; vitreous body; humans; retreatment; visual acuity; angiogenesis inhibitors; aged; angioid streaks; antibodies monoclonalInjectionsNeovascularizationOptical coherence tomographyOphthalmologyRanibizumabMedicineantibodiesHumansANTI-VEGFAgedintravitreal ranibizumabmedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoAntibodies MonoclonalGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseeye diseasesChoroidal NeovascularizationVitreous BodyOphthalmologyAngioid streaksChoroidal neovascularizationTreatment OutcomeRetreatmentAngioid StreaksFemalemedicine.symptomRanibizumabbusinessAngioid streak-related choroidal neovascularizationmedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Dynamic changes of the microtubule system corresponding to the unequal and spiral cleavage modes in the embryo of the zebra mussel, Dreissena polymor…

1998

Unequal cleavage requires a highly organised cytoskeleton. We investigated the localisation of both tubulins and microtubular arrays in Dreissena eggs during and after fertilisation using confocal laser scanning microscopy. Freshly spawned eggs are arrested in metaphase I. A maternal pool of γ-tubulin is found mainly in the centre of the asters of the meiotic spindle. The paternal pool of γ-tubulin, present in the fertilising sperm, could not be traced within the egg, but a microtubule-organising centre forms near the male pronucleus at anaphase II. Male and female pronuclei grow as they migrate in the wake of their aster and rendezvous. First cleavage is unequal and starts without pronucle…

MaleZygoteSpindle ApparatusAster (cell biology)BiologyCleavage (embryo)MicrotubulesTubulinAnimalsCleavage furrowMetaphaseCytoskeletonAnaphaseCell NucleusPronuclear fusionMicroscopy ConfocalPronucleusCell BiologyAnatomyMale pronucleusImmunohistochemistrySpermatozoaCell biologyBivalviaFertilizationOocytesCell DivisionDevelopmental BiologyZygote (Cambridge, England)
researchProduct

Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe

2005

International audience; Background: Resource utilisation and direct costs associated with glaucoma progression in Europe are unknown. As population progressively ages, the economic impact of the disease will increase. Methods: From a total of 1655 consecutive cases, the records of 194 patients were selected and stratified by disease severity. Record selection was based on diagnoses of primary open angle glaucoma, glaucoma suspect, ocular hypertension, or normal tension glaucoma; 5 years minimum follow up were required. Glaucoma severity was assessed using a six stage glaucoma staging system based on static threshold visual field parameters. Resource utilisation data were abstracted from the…

Maleage distributionOrganes des sensgenetic structuresOffice VisitsOcular hypertensionGlaucomaDiseaseintraocular hypertensionSeverity of Illness IndexIndirect costs0302 clinical medicineambulatory careNormal tension glaucomamiddle agedopen angle glaucoma80 and overMedicine030212 general & internal medicinepathophysiologystatistical significanceAged 80 and overeducation.field_of_studyadultdisease coursearticlehealth care costclinical trialHealth Care Costshealth care planningSensory Systems3. Good healthEuropeagedfemalepriority journalstatisticsHealth Resourcesdisease severityadult; aged; article; disease course; disease severity; Europe; female; follow up; general practitioner; glaucoma; health care cost; health care utilization; human; intraocular hypertension; major clinical study; male; medical record; open angle glaucoma; priority journal; statistical significance; visual field; age distribution; ambulatory care; clinical trial; drug cost; economics; health care planning; hospitalization; middle aged; multicenter study; pathophysiology; sex ratio; statistics; utilization review; Adult; Age Distribution; Aged; Aged 80 and over; Drug Costs; Europe; Female; Follow-Up Studies; Glaucoma; Health Care Costs; Health Resources; Humans; Male; Middle Aged; Office Visits; Severity of Illness Index; Sex Distribution; Visual Fieldshospitalizationvisual fieldWorld Viewsmedicine.medical_specialtyOpen angle glaucomadrug costPopulationSensory OrgansMédecine humaine et pathologiemedical recordDrug Costs03 medical and health sciencesCellular and Molecular Neurosciencehealth care utilizationSeverity of illnessfollow upHumanshumanSex Distribution[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organseducationutilization reviewSettore MED/30 - Malattie Apparato Visivobusiness.industryGlaucomaeconomicssex ratiomedicine.diseasemajor clinical studyeye diseasesOphthalmologymulticenter studygeneral practitionerEmergency medicine030221 ophthalmology & optometryOptometryHuman health and pathologyVisual Fieldsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

2016

BACKGROUND: Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia.METHODS: We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investig…

Maleantibiotic resistancePrevalenceMRSAmedicine.disease_causepneumonia; antibiotic resistance; staphylococcus aureus; MRSAGlobal HealthCohort Studies0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsRetrospective StudiePrevalenceCommunity-Acquired Infection030212 general & internal medicineeducation.field_of_studyCross InfectionRespiratory tract infectionsMethicillin-Resistant Staphylococcus aureuStaphylococcal InfectionsHospitalsCommunity-Acquired InfectionsInfectious DiseasesInfectious diseasesFemaleHumanMethicillin-Resistant Staphylococcus aureusstaphylococcus aureusmedicine.medical_specialtyPopulationAdmissionstaphylococcus aureuSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesHospitalInternal medicinemedicineHumanspneumoniaRisk factoreducationIntensive care medicineStaphylococcal InfectionRetrospective StudiesAgedbusiness.industryRisk FactorOdds ratioPneumoniamedicine.diseaseMethicillin-resistant Staphylococcus aureusPneumonia030228 respiratory systemMethicillin ResistanceCohort Studiebusiness
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct